Preview

Медицинский Совет

Расширенный поиск

Нарушения кишечного микробиоценоза: расширение сферы применения пробиотиков

https://doi.org/10.21518/2079-701X-2022-16-7-132-143

Полный текст:

Аннотация

Проблема взаимодействия человека и кишечного микробиома окружена множеством тайн и загадок. Бактериальная флора желудочно-кишечного тракта оказывает локальное и системное воздействие не только на органы пищеварения, но и на весь организм  в  целом.  Многочисленные  исследования  доказали   патогенетическую   связь  состояния   кишечного   биоценоза не только  с заболеваниями желудочно-кишечного  тракта, но и с патологическими  процессами  со  стороны  других органов    и систем организма. По своей роли в поддержании гомеостаза кишечная микрофлора не уступает любому другому жизненно важному органу. В представленном обзоре рассмотрены актуальные аспекты терминологии и клиники нарушений кишечного микробиоценоза. Важное место в комплексной терапии нарушений микробиоценоза кишечника и соответствующих им клинических проявлений занимают пробиотики. В рамках обзора рассмотрены основные механизмы взаимодействия «пробиотик/хозяин», неиммунологические и иммунологические эффекты пробиотиков и предъявляемые к ним требования, основные направления применения представителей нормальной микрофлоры Bifidobacterium и Lactobacillus. Приведены данные метаанализов и системных обзоров, свидетельствующих о расширении показаний к назначению пробиотиков, рассмотрены возможности пробиотиков в комплексной терапии хеликобактерной инфекции, синдрома повышенной эпителиальной проницаемости кишечника, профилактики респираторных инфекций. В заключении обзора приводятся результаты поиска в базе данных PubMed о возможности применения пробиотиков в профилактике и лечении новой коронавирусной инфекции COVID-19.

Наличие в арсенале практического врача (прежде всего терапевта и врача общей практики) современных, эффективных и безопасных пробиотиков и их применение способствуют оптимизации лекарственной терапии не только у пациентов гастроэнтерологического профиля, но и у пациентов с другой соматической патологией, в т. ч. и с новой коронавирусной инфекцией COVID-19.

Об авторе

Д. И. Трухан
Омский государственный медицинский университет
Россия

Трухан Дмитрий Иванович - доктор медицинских наук, доцент, профессор кафедры поликлинической терапии и внутренних болезней.

644043, Омск, ул. Ленина, д. 12.



Список литературы

1. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение. СПб.; 2013. 144 с.

2. Харитонова Л.А., Григорьев К.И., Борзакова С.Н. Микробиота человека: как новая научная парадигма меняет медицинскую практику. Экспериментальная и клиническая гастроэнтерология. 2019;(1):55–63. https://doi.org/10.31146/1682-8658-ecg-161-1-55-63.

3. Юдина Ю.В., Корсунский А.А., Аминова А.И., Абдуллаева Г.Д., Продвус А.П. Микробиота кишечника как отдельная система организма. Доказательная гастроэнтерология. 2019;(4):36–43. https://doi.org/10.17116/dokgastro2019804-05136.

4. Кайбышева В.О., Жарова М.Е., Филимендикова К.Ю., Никонов Е.Л. Микробиом человека: возрастные изменения и функции. Доказательная гастроэнтерология. 2020;(2):42–55. https://doi.org/10.17116/dokgastro2020902142.

5. Комарова О.Н., Хавкин А.И. Взаимосвязь стресса, иммунитета и кишечной микробиоты. Педиатрическая фармакология. 2020;(1):18–24. https://doi.org/10.15690/pf.v17i1.2078.

6. Ардатская М.Д., Бельмер С.В., Добрица В.П., Захаренко С.М., Лазебник Л.Б., Минушкин О.Н. и др. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция. Экспериментальная и клиническая гастроэнтерология. 2015;(5):13–50. Режим доступа: https://cyberleninka.ru/article/n/disbioz-disbakterioz-kishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-i-lechebnaya-korrektsiya.

7. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.; 2016. 168 с.

8. Трухан Д.И., Филимонов С.Н. Заболевания кишечника: клиника, диагностика и лечение. Новокузнецк; 2017. 223 с.

9. Bouhnik Y., Alain S., Attar A., Flourié B., Raskine L., Sanson-Le Pors M.J., Rambaud J.C. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94(5):1327–1331. https://doi.org/10.1111/j.1572-0241.1999.01016.x.

10. Stein J.M., Schneider A.R. Bacterial overgrowth syndrome. Z Gastroenterol. 2007;45(7):620–628. https://doi.org/10.1055/s-2007-963045.

11. Quigley E.M. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30(2):141–146. https://doi.org/10.1097/MOG.0000000000000040.

12. Guarner F., Khan A.G., Garisch J., Eliakim R., Gangl А., Thomson А. et al. Пробиотики и пребиотики. Глобальные практические рекомендации Всемирной гастроэнтерологической организации. 2008. 37 с. Режим доступа: https://www.worldgastroenterology.org/UserFiles/file/guide-lines/probiotics-and-prebiotics-russian-2017.pdf.

13. Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.E. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016;19:262. https://doi.org/10.1186/s13054-016-1434-y.

14. Sebastian Domingo J.J. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol. 2017;40(6):417–429. https://doi.org/10.1016/j.gastrohep.2016.12.003.

15. Hütt P., Shchepetova J., Lõivukene K., Kullisaar T., Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl Microbiol. 2006;100(6):1324–1332. https://doi.org/10.1111/j.1365-2672.2006.02857.x.

16. McFarland L.V. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5(2):97–105. https://doi.org/10.1016/j.tmaid.2005.10.003.

17. Singhi S.C., Baranwal A. Probiotic use in the critically ill. Indian J Pediatr. 2008;75(6):621–627. https://doi.org/10.1007/s12098-008-0119-1.

18. Turroni F., Duranti S., Milani C., Lugli G.A., van Sinderen D., Ventura M. Bifidobacterium bifidum: A Key Member of the Early Human Gut Microbiota. Microorganisms. 2019;7(11):544. https://doi.org/10.3390/microorganisms7110544.

19. Dongarrà M.L., Rizzello V., Muccio L., Fries W., Cascio A., Bonaccorsi I., Ferlazzo G. Mucosal immunology and probiotics. Curr Allergy Asthma Rep. 2013;13(1):19–26. https://doi.org/10.1007/s11882-012-0313-0.

20. Arboleya S., Watkins C., Stanton C., Ross R.P. Gut Bifidobacteria Populations in Human Health and Aging. Front Microbiol. 2016;7:1204. https://doi.org/10.3389/fmicb.2016.01204.

21. Kalyuzhin O.V., Afanasyev S.S., Bykov A.S. Probiotics as stimulators of immune response against pathogens in the respiratory tract. Ter Arkh. 2016;88(5):118–124. https://doi.org/10.17116/terarkh2016885118-124.

22. Melli L.C., do Carmo-Rodrigues M.S., Araújo-Filho H.B., Solé D., de Morais M.B. Intestinal microbiota and allergic diseases: A systematic review. Allergol Immunopathol (Madr). 2016;44(2):177–188. https://doi.org/10.1016/j.aller.2015.01.013.

23. Tan-Lim C.S.C., Esteban-Ipac N.A.R., Mantaring J.B.V. 3rd, Chan Shih Yen E., Recto M.S.T., Sison O.T., Alejandria M.M. Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis. Pediatr Allergy Immunol. 2021;32(1):124–136. https://doi.org/10.1111/pai.13305.

24. Xie C., Li J., Wang K., Li Q., Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis. 2015;13(2):128–134. https://doi.org/10.1016/j.tmaid.2015.03.001.

25. McFarland L.V. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiotics (Basel). 2015;4(2):160–178. https://doi.org/10.3390/antibiotics4020160.

26. Hamilton-Miller J.M. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents. 2003;22(4):360–366. https://doi.org/10.1016/s0924-8579(03)00153-5.

27. Cruchet S., Furnes R., Maruy A., Hebel E., Palacios J., Medina F. et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17(3):199–216. https://doi.org/10.1007/s40272-015-0124-6.

28. Feng J.R., Wang F., Qiu X., McFarland L.V., Chen P.F., Zhou R. et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017;73(10):1199–1208. https://doi.org/10.1007/s00228-017-2291-6.

29. Eslami M., Yousefi B., Kokhaei P., Jazayeri Moghadas A., Sadighi Moghadam B., Arabkari V., Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99–108. https://doi.org/10.1016/j.cimid.2019.02.010.

30. Martínez-Martínez M.I., Calabuig-Tolsá R., Cauli O. The effect of probiotics as a treatment for constipation in elderly people: A systematic review. Arch Gerontol Geriatr. 2017;71:142–149. https://doi.org/10.1016/j.arch-ger.2017.04.004.

31. Ortiz-Lucas M., Tobías A., Saz P., Sebastián J.J. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105(1):19–36. https://doi.org/10.4321/s1130-01082013000100005.

32. Шульпекова Ю.О., Курбатова А.А., Седова А.В. Запор функционального происхождения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;(5):105–112. Режим доступа: https://www.gastro-j.ru/jour/article/view/186/160.

33. Sela D.A. Bifidobacterial utilization of human milk oligosaccharides. Int J Food Microbiol. 2011;149(1):58–64. https://doi.org/10.1016/j.ijfoodmicro.2011.01.025.

34. Chichlowski M., Shah N., Wampler J.L., Wu S.S., Vanderhoof J.A. Bifidobacterium longum Subspecies infantis (B. infantis) in Pediatric Nutrition: Current State of Knowledge. Nutrients. 2020;12(6):1581. https://doi.org/10.3390/nu12061581.

35. Underwood M.A., German J.B., Lebrilla C.B., Mills D.A. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res. 2015;77(1–2):229–235. https://doi.org/10.1038/pr.2014.156.

36. Ganguli K., Walker W.A. Probiotics in the prevention of necrotizing enterocolitis. J Clin Gastroenterol. 2011;(45 Suppl.):S133–138. https://doi.org/10.1097/MCG.0b013e318228b799.

37. Ritchie M.L., Romanuk T.N. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE. 2012;7(4):e34938. https://doi.org/10.1371/journal.pone.0034938.

38. Kutylowksi J., Yahia N. Types, Frequency, Duration, and Dosage of Probiotics to Prevent Necrotizing Enterocolitis in Preterm Infants Among Countries. Adv Neonatal Care. 2019;19(3):188–197. https://doi.org/10.1097/ANC.0000000000000605.

39. Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033–1049; quiz 1050. Available at: https://pubmed.ncbi.nlm.nih.gov/19277023.

40. Schmulson M., Chang L. Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther. 2016;63(Suppl. 1):S25–S26. https://doi.org/10.1111/j.1365-2036.2011.04637.x.

41. Giannetti E., Staiano A. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. J Pediatr Gastroenterol Nutr. 2016;(63 Suppl. 1):S25–26. Available at: https://pubmed.ncbi.nlm.nih.gov/27380595.

42. Yuan F., Ni H., Asche C.V., Kim M., Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191–1197. https://doi.org/10.1080/03007995.2017.1292230.

43. Groeger D., O’Mahony L., Murphy E.F., Bourke J.F., Dinan T.G., Kiely B. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–339. https://doi.org/10.4161/gmic.25487.

44. Konieczna P., Groeger D., Ziegler M., Frei R., Ferstl R., Shanahan F. et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut. 2012;61(3):354–366. https://doi.org/10.1136/gutjnl-2011-300936.

45. Goldstein E.J., Tyrrell K.L., Citron D.M. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis. 2015;60(Suppl. 2):S98–S107. https://doi.org/10.1093/cid/civ072.

46. Hill D., Sugrue I., Tobin C., Hill C., Stanton C., Ross R.P. The Lactobacillus casei Group: History and Health Related Applications. Front Microbiol. 2018;9:2107. https://doi.org/10.3389/fmicb.2018.02107.

47. Ashraf R., Shah N.P. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938–956. https://doi.org/10.1080/10408398.2011.619671.

48. Goldstein E.J.C., Johnson S.J., Maziade P.J., Evans C.T., Sniffen J.C., Millette M., McFarland L.V. Probiotics and prevention of Clostridium difficile infection. Anaerobe. 2017;45:114–119. https://doi.org/10.1016/j.anaerobe.2016.12.007.

49. Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4):21. https://doi.org/10.3390/antibiotics6040021.

50. Valdés-Varela L., Gueimonde M., Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. Adv Exp Med Biol. 2018;1050:161–176. https://doi.org/10.1007/978-3-319-72799-8_10.

51. McFarland L.V., Goh S. Are probiotics and prebiotics effective in the prevention of travellers’ diarrhea: A systematic review and meta-analysis. Travel Med Infect Dis. 2019;27:11–19. https://doi.org/10.1016/j.tmaid.2018.09.007.

52. Ng Q.X., Peters C., Venkatanarayanan N., Goh Y.Y., Ho C.Y.X., Yeo W.S. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses. 2018;114:49–54. https://doi.org/10.1016/j.mehy.2018.03.001.

53. Amaral M.A., Guedes G.H.B.F., Epifanio M., Wagner M.B., Jones M.H., Mattiello R. Network meta-analysis of probiotics to prevent respiratory infections in children and adolescents. Pediatr Pulmonol. 2017;52(6):833–843. https://doi.org/10.1002/ppul.23643.

54. Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019;53(1 Suppl.):S1–S41. https://doi.org/10.1097/MCG.0000000000001170.

55. Wojtyniak K., Szajewska H. Systematic review: probiotics for functional constipation in children. Eur J Pediatr. 2017;176(9):1155–1162. https://doi.org/10.1007/s00431-017-2972-2.

56. Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019;1125:121–137. https://doi.org/10.1007/5584_2018_321.

57. McFarland L.V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016;4(4):546–561. https://doi.org/10.1177/2050640615617358.

58. Han Y.M., Park J.M., Jeong M., Yoo J.H., Kim W.H., Shin S.R. et al. Dietary, non-microbial intervention to prevent Helicobacter pylori-associated gastric diseases. Ann Transl Med. 2015;3(9):122. https://doi.org/10.3978/j.issn.2305-5839.2015.03.50.

59. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T. et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288.

60. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155–168. https://doi.org/10.1111/j.1365-2036.2006.03179.x.

61. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. https://doi.org/10.1097/MCG.0b013e318266f6cf.

62. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445–453. https://doi.org/10.4321/s1130-01082013000800002.

63. Zhu R., Chen K., Zheng Y.-Y., Zhang H.W., Wang J.S. Xia Y.J. et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014;20(47):18013–18021. https://doi.org/10.3748/wjg.v20.i47.18013.

64. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS ONE. 2014;9(11):e111030. https://doi.org/10.1371/journal.pone.0111030.

65. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707–716. https://doi.org/10.3892/etm.2015.2174.

66. Zhang M-M., Qian W., Qin Y-Y., He J., Zhou J.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastro­ enterol. 2015;21(14):4345–4357. https://doi.org/10.3748/wjg.v21.i14.4345.

67. Arrieta M.C., Bistritz L., Meddings J.B. Alterations in intestinal permeability. Gut. 2006;55(10):1512–1520. https://doi.org/10.1136/gut.2005.085373.

68. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809. https://doi.org/10.1038/nri2653.

69. Odenwald M.A., Turner J.R. Intestinal permeability defects: Is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075–1083. https://doi.org/10.1016/j.cgh.2013.07.001.

70. Graziani C., Talocco C., De Sire R., Petito V., Lopetuso L.R., Gervasoni J. et al. Intestinal Permeability in Physiological and Pathological Conditions: Major Determinants and Assessment Modalities. Eur Rev Med Pharmacol Sci. 2019;23(2):795–810. https://doi.org/10.26355/eurrev_201901_16894.

71. Sturgeon C., Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016;4(4):e1251384. https://doi.org/10.1080/21688370.2016.1251384.

72. Matysiak-Budnik T., Heyman M., Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18(Suppl. 1):55–62. https://doi.org/10.1046/j.1365-2036.18.s1.6.x.

73. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016;1(3):135–145. https://doi.org/10.1159/000447252.

74. Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22–28. https://doi.org/10.1159/000452356.

75. Wells J.M. Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact. 2011;10 Suppl. 1 (Suppl. 1):S17. https://doi.org/10.1186/1475-2859-10-S1-S17.

76. Cong Y., Feng T., Fujihashi K., Schoeb T.R., Elson C.O. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA. 2009;106(46):19256–19261. https://doi.org/10.1073/pnas.0812681106.

77. Smith P.M., Garrett W.S. The gut microbiota and mucosal T cells. Front Microbiol. 2011;2:111. https://doi.org/10.3389/fmicb.2011.00111.

78. Taverniti V., Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 2011;6(3):261–274. https://doi.org/10.1007/s12263-011-0218-x.

79. Калюжин О.В. Пробиотические штаммы лактобацилл как иммуномодуляторы: в фокусе – Lactobacillus rhamnosus GG. Медицинский совет. 2017;(9):108–115. https://doi.org/10.21518/2079-701X-2017-9-108-115.

80. Abt M.C., Osborne L.C., Monticelli L.A., Doering T.A., Alenghat T., Sonnenberg G.F. et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012;37(1):158–170. https://doi.org/10.1016/j.immuni.2012.04.011.

81. Булгакова В.А., Балаболкин И.И., Ушакова В.В. Современное состояние проблемы часто болеющих детей. Педиатрическая фармакология. 2007;(2): 48–52. Режим доступа: https://www.pedpharma.ru/jour/article/view/643.

82. Трухан Д.И., Викторова И.А. Коррекция нарушений кишечного микробиоценоза в аспекте профилактики респираторных инфекций дыхательных путей: возможности Lactobacillus rhamnosus GG. Consilium Medicum. 2018;(2):39–44. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2018/gastro2018_pril/gastro2018_2_pril/korrektsiya-narusheniy-kishechnogo-mikrobiotsenoza-v-aspekte-profilaktiki-respiratornykh-infektsiy-d/.

83. Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;(4):2630. https://doi.org/10.15829/1728-8800-2020-2630.

84. Княжеская Н.П. Иммунотерапия хронических заболеваний легких. Consilium Medicum. 2014;(3):42–48. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2014/cm2014_3_pulmo/immunoterapiya-khronicheskikh-zabolevaniy-legkikh/.

85. Johnstone J., Meade M., Marshall J., Heyland D.K., Surette M.G., Bowdish D.M. et al. Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: protocol for a feasibility randomized pilot trial. Pilot Feasibility Stud. 2015;1:19. https://doi.org/10.1186/s40814-015-0013-3.

86. van den Broek M.F.L., De Boeck I., Claes I.J.J., Nizet V., Lebeer S. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis. Benef Microbes. 2018;9(3):429–439. https://doi.org/10.3920/BM2017.0101.

87. Kalima K., Lehtoranta L., He L., Pitkäniemi J., Lundell R., Julkunen I. et al. Probiotics and respiratory and gastrointestinal tract infections in Finnish military conscripts – a randomised placebo-controlled double-blinded study. Benef Microbes. 2016;7(4):463–471. https://doi.org/10.3920/BM2015.0172.

88. Tapiovaara L., Kumpu M., Mäkivuokko H., Waris M., Korpela R., Pitkäranta A., Winther B. Human rhinovirus in experimental infection after peroral Lactobacillus rhamnosus GG consumption, a pilot study. Int Forum Allergy Rhinol. 2016;6(8):848–853. https://doi.org/10.1002/alr.21748.

89. Wang B., Hylwka T., Smieja M., Surrette M., Bowdish D.M.E., Loeb M. Probiotics to Prevent Respiratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial. J Am Geriatr Soc. 2018;66(7):1346–1352. https://doi.org/10.1111/jgs.15396.

90. Laursen R.P., Hojsak I. Probiotics for respiratory tract infections in children attending day care centers-a systematic review. Eur J Pediatr. 2018;177(7):979–994. https://doi.org/10.1007/s00431-018-3167-1.

91. Youssef M., Ahmed H.Y., Zongo A., Korin A., Zhan F., Hady E. et al. Probiotic Supplements: Their Strategies in the Therapeutic and Prophylactic of Human Life-Threatening Diseases. Int J Mol Sci. 2021;22(20):11290. https://doi.org/10.3390/ijms222011290.

92. Manzoor S., Wani S.M., Ahmad Mir S., Rizwan D. Role of probiotics and prebiotics in mitigation of different diseases. Nutrition. 2022;96:111602. https://doi.org/10.1016/j.nut.2022.111602.

93. Roy K., Agarwal S., Banerjee R., Paul M.K., Purbey P.K. COVID-19 and gut immunomodulation. World J Gastroenterol. 2021;27(46):7925–7942. https://doi.org/10.3748/wjg.v27.i46.7925.

94. Venegas-Borsellino C., Sankararaman S., Roche K., Burns J., Landis R.M. Impact of COVID-19 on the Intestinal Microbiome. Curr Nutr Rep. 2021;10(4):300–306. https://doi.org/10.1007/s13668-021-00375-z.

95. Skrajnowska D., Brumer M., Kankowska S., Matysek M., Miazio N., Bobrowska-Korczak B. Covid 19: Diet Composition and Health. Nutrients. 2021;13(9):2980. https://doi.org/10.3390/nu13092980.

96. Трухан Д.И., Давыдов Е.Л. Место и роль терапевта и врача общей практики в курации коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19): акцент на неспецифическую профилактику. Фарматека. 2021;(10):34–45. https://doi.org/10.18565/pharmateca.2021.13.44-53.

97. Трухан Д.И., Давыдов Е.Л., Чусова Н.А. Нутрицевтики в профилактике, лечении и на этапе реабилитации после новой коронавирусной инфекции (COVID-19). Клинический разбор в общей медицине. 2021;(7):21–34. https://doi.org/10.47407/kr2021.2.7.00085.

98. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных симптомов и синдромов при заболеваниях желудочно­кишечного тракта. Новокузнецк; 2022. 234 с. Режим доступа: https://www.elibrary.ru/item.asp?id=48177755.

99. Jabczyk M., Nowak J., Hudzik B., Zubelewicz-Szkodzińska B. Diet, Probiotics and Their Impact on the Gut Microbiota during the COVID-19 Pandemic. Nutrients. 2021;13(9):3172. https://doi.org/10.3390/nu13093172.

100. Di Renzo L., Gualtieri P., Pivari F., Soldati L., Attinà A., Leggeri C. et al. COVID-19: Is there a role for immunonutrition in obese patient? J Transl Med. 2020;18(1):415. https://doi.org/10.1186/s12967-020-02594-4.

101. Majewski S., Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci. 2015;11(6):1179–1188. https://doi.org/10.5114/aoms.2015.56343.

102. Симаненков В.И., Маев И.В., Ткачева О.Н, Алексеенко С.А., Андреев Д.Н., Бордин Д.С. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;(1):2758. https://doi.org/10.15829/1728-8800-2021-2758.

103. Трухан Д.И., Иванова Д.С. Роль и место синдрома повышенной эпителиальной проницаемости в развитии сердечно-сосудистых и бронхолегочных заболеваний: теоретические и практические аспекты применения ребамипида. Фарматека. 2021;(5):115–126. https://doi.org/10.18565/pharmateca.2021.5.115-126.

104. Khan A.A., Singh H., Bilal M., Ashraf M.T. Microbiota, probiotics and respiratory infections: the three musketeers can tip off potential management of COVID-19. Am J Transl Res. 2021;13(10):10977–10993. Available at: https://pubmed.ncbi.nlm.nih.gov/34786037.

105. Konturek P.C. How does COVID-19 affect intestinal microbiota? MMW Fortschr Med. 2021;163(Suppl. 5):17–20. https://doi.org/10.1007/s15006-021-0200-5.

106. Baradaran Ghavami S., Pourhamzeh M., Farmani M., Raftar S.K.A., Shahrokh S., Shpichka A. et al. Cross-talk between immune system and microbiota in COVID-19. Expert Rev Gastroenterol Hepatol. 2021;15(11):1281–1294. https://doi.org/10.1080/17474124.2021.1991311.

107. Xavier-Santos D., Padilha M., Fabiano G.A., Vinderola G., Gomes Cruz A., Sivieri K., Costa Antunes A.E. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review. Trends Food Sci Technol. 2022;120:174–192. https://doi.org/10.1016/j.tifs.2021.12.033.

108. Wang H., Wang H., Sun Y., Ren Z., Zhu W., Li A., Cui G. Potential Associations Between Microbiome and COVID-19. Front Med (Lausanne). 2021;8:785496. https://doi.org/10.3389/fmed.2021.785496.

109. Mirashrafi S., Moravejolahkami A.R., Balouch Zehi Z., Hojjati Kermani M.A., Bahreini-Esfahani N., Haratian M. Et al. The efficacy of probiotics on virus titres and antibody production in virus diseases: A systematic review on recent evidence for COVID-19 treatment. Clin Nutr ESPEN. 2021;46:1–8. https://doi.org/10.1016/j.clnesp.2021.10.016.

110. Kasti A.N., Synodinou K.D., Pyrousis I.A., Nikolaki M.D., Triantafyllou K.D. Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19. Microorganisms. 2021;9(11):2376. https://doi.org/10.3390/microorganisms9112376.

111. Akour A. Probiotics and COVID-19: is there any link? Lett Appl Microbiol. 2020;71(3):229–234. https://doi.org/10.1111/lam.13334.

112. Bottari B., Castellone V., Neviani E. Probiotics and Covid-19. Int J Food Sci Nutr. 2021;72(3):293–299. https://doi.org/10.1080/09637486.2020.1807475.

113. Parisi G.F., Carota G., Castruccio Castracani C., Spampinato M., Manti S., Papale M. et al. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature. Int J Mol Sci. 2021;22(5):2465. https://doi.org/10.3390/ijms22052465.

114. Batista K.S., de Albuquerque J.G., Vasconcelos M.H.A., Bezerra M.L.R., da Silva Barbalho M.B., Pinheiro R.O., Aquino J.S. Probiotics and prebiotics: potential prevention and therapeutic target for nutritional management of COVID-19? Nutr Res Rev. 2021;1–18. https://doi.org/10.1017/S0954422421000317.

115. Angurana S.K., Bansal A. Probiotics and Coronavirus disease 2019: think about the link. Br J Nutr. 2021;126(10):1564–1570. https://doi.org/10.1017/S000711452000361X.

116. Hawryłkowicz V., Lietz-Kijak D., Kaźmierczak-Siedlecka K., Sołek-Pastuszka J., Stachowska L., Folwarski M. et al. Patient Nutrition and Probiotic Therapy in COVID-19: What Do We Know in 2021? Nutrients. 2021;13(10):3385. https://doi.org/10.3390/nu13103385.

117. Nayebi A., Navashenaq J.G., Soleimani D., Nachvak S.M. Probiotic supplementation: A prospective approach in the treatment of COVID-19. Nutr Health. 2021:2601060211049631. https://doi.org/10.1177/02601060211049631.

118. Rozga M., Cheng F.W., Handu D. Effects of Probiotics in Conditions or Infections Similar to COVID-19 on Health Outcomes: An Evidence Analysis Center Scoping Review. J Acad Nutr Diet. 2021;121(9):1841–1854. https://doi.org/10.1016/j.jand.2020.07.016.

119. Szychowiak P., Villageois-Tran K., Patrier J., Timsit J.F., Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care. 2022;12(1):3. https://doi.org/10.1186/s13613-021-00976-5.

120. Serek P., Oleksy-Wawrzyniak M. The Effect of Bacterial Infections, Probiotics and Zonulin on Intestinal Barrier Integrity. Int J Mol Sci. 2021;22(21):11359. https://doi.org/10.3390/ijms222111359.

121. Peng J., Zhang M., Yao G., Kwok L.Y., Zhang W. Probiotics as Adjunctive Treatment for Patients Contracted COVID-19: Current Understanding and Future Needs. Front Nutr. 2021;8:669808. https://doi.org/10.3389/fnut.2021.669808.

122. Nguyen Q.V., Chong L.C., Hor Y.Y., Lew L.C., Rather I.A., Choi S.B. Role of Probiotics in the Management of COVID-19: A Computational Perspective. Nutrients. 2022;14(2):274. https://doi.org/10.3390/nu14020274.

123. Ivashkin V., Fomin V., Moiseev S., Brovko M., Maslennikov R., Ulyanin A. et al. Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiotics Antimicrob Proteins. 2021;1–9. https://doi.org/10.1007/s12602-021-09858-5.

124. Gutiérrez-Castrellón P., Gandara-Martí T., Abreu Y. Abreu A.T., NietoRufino C.D., López-Orduña E., Jiménez-Escobar I. et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. https://doi.org/10.1080/19490976.2021.2018899.

125. Kageyama Y., Nishizaki Y., Aida K., Yayama K., Ebisui T., Akiyama T., Nakamura T. Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefit against COVID-19: A single-arm, double-blind, prospective trial combined with an in vitro cytokine response assay. Exp Ther Med. 2022;23(1):20. https://doi.org/10.3892/etm.2021.10942.

126. Zhang L., Xu Z., Mak J.W.Y., Chow K.M., Lui G., Li T.C.M. et al. Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study. J Gastroenterol Hepatol. 2022. https://doi.org/10.1111/jgh.15796.

127. Alharbi K.S., Singh Y., Hassan Almalki W., Rawat S., Afzal O., Alfawaz Altamimi A.S. et al. Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre / Probiotics in manipulating microflora. Chem Biol Interact. 2022;358:109898. https://doi.org/10.1016/j.cbi.2022.109898.

128. El-Sayed E.M., Ibrahim K.S. Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. Mol Biol Rep. 2022;1–11. https://doi.org/10.1007/s11033-022-07226-2.

129. Rathi A., Jadhav S.B., Shah N. A Randomized Controlled Trial of the Efficacy of Systemic Enzymes and Probiotics in the Resolution of Post-COVID Fatigue. Medicines (Basel). 2021;8(9):47. https://doi.org/10.3390/medicines8090047.

130. Heidari Z., Tajbakhsh A., Gheibihayat S.M., Moattari A., Razban V., Berenjian A. et al. Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens. Recent Pat Biotechnol. 2021;15(2):112–136. https://doi.org/10.2174/1872208315666210419103742.


Рецензия

Для цитирования:


Трухан Д.И. Нарушения кишечного микробиоценоза: расширение сферы применения пробиотиков. Медицинский Совет. 2022;(7):132-143. https://doi.org/10.21518/2079-701X-2022-16-7-132-143

For citation:


Trukhan D.I. Disorders of intestinal microbiocenosis: expanding the application of probiotics. Meditsinskiy sovet = Medical Council. 2022;(7):132-143. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-7-132-143

Просмотров: 84


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)